Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,881.30 -2,266.13 (-3.59%) CMC Crypto 200
1,261.66 -96.35 (-7.09%)
MeiraGTx Holdings plc (MGTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 5.10 |
| Open | 5.17 |
| Bid | 5.06 x 100 |
| Ask | 5.10 x 100 |
| Day's range | 4.95 - 5.28 |
| 52-week range | 3.49 - 8.35 |
| Volume | |
| Avg. volume | 147,582 |
| Market cap | 326.034M |
| Beta (5Y monthly) | 1.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.49 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.60 |
GuruFocus.comMeiraGTx Holdings PLC Reports First Quarter 2024 Financial Results
Performance Aligns with Analyst Projections Amidst Strategic Clinical Advancements
Simply Wall St.MeiraGTx Holdings First Quarter 2024 Earnings: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023)
MeiraGTx Holdings ( NASDAQ:MGTX ) First Quarter 2024 Results Key Financial Results Revenue: US$697.0k (down 79% from 1Q...
GlobeNewswireMeiraGTx Reports First Quarter 2024 Financial and Operational Results
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Received $50 million milestone following initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) - Clinical development milestones met and remain on track for the re
© 2024 Yahoo. All rights reserved.